Prostate Cancer Market Segmentation:
- By Treatment Type
- Hormone Therapy
- Chemotherapy
- Immunotherapy
- Targeted Therapy
- Surgery
- Radiation Therapy
- Others
- By End User
- Hospitals
- Cancer Research Institutes
- Ambulatory Surgical Centers
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Stage
- Localized
- Locally Advanced
- Metastatic
- Castration-Resistant
- By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Frequently Asked Questions
The Prostate Cancer market was valued at USD 9.7 billion in 2023.
Rising incidence of prostate cancer globally, Growing elderly male population, Advances in screening, diagnosis and treatment technologies, Higher healthcare expenditure and awareness, Strong product pipeline
High cost of therapeutic drugs and procedures, Reimbursement restrictions in developing markets, Adverse side effects of treatments, Low screening rates in developing countries
Hormone therapy drugs like LHRH agonists and anti-androgens are the leading segment, occupying over 40% of the prostate cancer therapeutics market currently. These drugs slow cancer progression by reducing testosterone levels.
Johnson & Johnson, Pfizer, Astellas Pharma, AstraZeneca, Bayer, Novartis, AbbVie, Sanofi, Bristol Myers Squibb, Roche, Merck, Ipsen, Ferring Pharmaceuticals, Takeda, Teva Pharmaceuticals, Janssen Biotech.
The market is projected to grow at a CAGR of 8.9% from 2023 to 2030. The market size is expected to reach US$ 17.7 billion by 2030.